Treatment of “triple-negative” breast cancer
For establishing diagnosis of breast cancer (BC), physicians test and classify tumor based on the presence of estrogen-, progesterone- and HER2-receptors. In some cases, the tumor is negative for all three receptors, in connection with which this subtype of cancer is often called "triple-negative" breast cancer. This is a very aggressive form of cancer characterized by a high level of metastasis and low survival rate compared with other subtypes of breast cancer. In the "triple negative" breast cancer, there is no single standard of treatment. Despite the poor prognosis, “triple-negative” breast cancer is sensitive to standard chemotherapy schemes, including anthracycline- and taksan-bearing schemes, but some patients do not respond to standard therapy. At the present time, alternative chemotherapeutic agents such as platinum compounds, topoisomerase inhibitors, anti-angiogenic and others drugs, in the neoadjuvant, adjuvant and therapeutic regimens are discussed.

Keywords: “triple-negative” breast cancer, breast cancer, gene expression